AOMS1
MCID: ABD014
MIFTS: 61

Abdominal Obesity-Metabolic Syndrome 1 (AOMS1)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 58 12 15
Metabolic Syndrome X 58 12 77 30 56 74
Metabolic Syndrome 45 64 41 17
Abdominal Obesity Metabolic Syndrome 74
Dysmetabolic Syndrome X 12
Aoms1 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
abdominal obesity-metabolic syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:14221
OMIM 58 605552
ICD9CM 36 277.7
MeSH 45 D024821
NCIt 51 C84442
ICD10 34 E88.81
MedGen 43 C4552048

Summaries for Abdominal Obesity-Metabolic Syndrome 1

OMIM : 58 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552)

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to abdominal obesity-metabolic syndrome quantitative trait locus 2 and fatty liver disease, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Developmental Biology and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Ezetimibe and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and endothelial, and related phenotypes are hypertension and abdominal obesity

Disease Ontology : 12 An abdominal obesity-metabolic syndrome characterized by insulin resistance and hyperinsulinemia, dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin-dependent diabetes mellitus and an increased risk of cardiovascular events.

PubMed Health : 64 About metabolic syndrome: Metabolic (met-ah-BOL-ik) syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke.The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease.In this article, "heart disease" refers to coronary heart disease (CHD). CHD is a condition in which a waxy substance called plaque (plak) builds up inside the coronary (heart) arteries.Plaque hardens and narrows the arteries, reducing blood flow to your heart muscle. This can lead to chest pain, a heart attack, heart damage, or even death.

Wikipedia : 77 Metabolic syndrome, sometimes known by other names, is a clustering of at least three of the five... more...

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

Diseases in the Abdominal Obesity-Metabolic Syndrome 1 family:

Abdominal Obesity-Metabolic Syndrome 3

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 539)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome quantitative trait locus 2 32.4 INS LEP SLC2A4
2 fatty liver disease 31.5 ADIPOQ INS LEP
3 nonalcoholic fatty liver disease 30.4 ADIPOQ INS LEP
4 liver disease 30.2 ADIPOQ INS LEP MEG3
5 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.2 ADIPOQ INS
6 hyperinsulinism 30.0 INS LEP SERPINE1
7 sleep apnea 30.0 ADIPOQ INS LEP
8 nonalcoholic steatohepatitis 29.9 ADIPOQ INS LEP
9 chronic kidney failure 29.8 ADIPOQ INS LEP
10 apnea, obstructive sleep 29.7 ADIPOQ INS LEP
11 fatty liver disease, nonalcoholic 1 29.5 ADIPOQ INS LEP MTTP
12 pre-eclampsia 29.4 ADIPOQ LEP SERPINE1
13 atherosclerosis susceptibility 29.4 ADIPOQ INS PPARG SERPINE1
14 hypertension, essential 29.4 ADIPOQ INS LEP SERPINE1
15 alstrom syndrome 29.4 INS LEP
16 gestational diabetes 29.3 ADIPOQ INS LEP SLC2A4
17 arteries, anomalies of 29.3 ADIPOQ INS LEP PPARG SERPINE1
18 cerebrovascular disease 29.1 ADIPOQ INS MEG3 SERPINE1
19 familial partial lipodystrophy 29.1 INS LEP PPARG
20 glucose intolerance 29.0 ADIPOQ INS LEP PPARG SLC2A4
21 coronary heart disease 1 29.0 ADIPOQ INS SERPINE1
22 acanthosis nigricans 29.0 ADIPOQ INS LEP PPARG
23 liver cirrhosis 29.0 ADIPOQ LEP MEG3
24 prader-willi syndrome 28.9 ADIPOQ INS LEP
25 arteriosclerosis 28.9 ADIPOQ INS PPARG SERPINE1
26 large intestine cancer 28.7 ADIPOQ INS PPARG
27 inherited metabolic disorder 28.6 ADIPOQ INS LEP
28 vascular disease 28.6 ADIPOQ INS PPARG SERPINE1
29 severe pre-eclampsia 28.6 ADIPOQ LEP
30 hyperglycemia 28.6 ADIPOQ INS LEP PPARG
31 3-hydroxyacyl-coa dehydrogenase deficiency 28.5 ADIPOQ INS LEP PPARG
32 body mass index quantitative trait locus 11 28.0 ADIPOQ HSD11B1 INS LEP MTTP PPARG
33 lipid metabolism disorder 27.9 ADIPOQ INS LEP MTTP PPARG SERPINE1
34 diabetes mellitus, noninsulin-dependent 27.7 ADIPOQ HSD11B1 INS LEP MTTP PPARG
35 diabetes mellitus 27.6 ADIPOQ INS LEP MEG3 PPARG SERPINE1
36 glucose metabolism disease 27.5 ADIPOQ INS LEP PPARG SERPINE1 SLC2A4
37 overnutrition 27.4 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
38 abdominal obesity-metabolic syndrome 3 12.4
39 polycystic ovary syndrome 11.2
40 gracile syndrome 11.2
41 gallbladder disease 1 11.1
42 smith-lemli-opitz syndrome 10.7
43 diabetes mellitus, noninsulin-dependent, 1 10.7
44 glaucoma, normal tension 10.7
45 diabetes mellitus, noninsulin-dependent, 5 10.7
46 peroneal nerve paralysis 10.7
47 47, xxy 10.7
48 coronary artery anomaly 10.3
49 schizophrenia 10.3
50 impotence 10.3

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

33
# Description HPO Frequency HPO Source Accession
1 hypertension 33 HP:0000822
2 abdominal obesity 33 HP:0012743

Symptoms via clinical synopsis from OMIM:

58
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
elevated fasting glucose levels

Growth Weight:
abdominal obesity

Clinical features from OMIM:

605552

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 ADIPOQ HSD11B1 INS LEP MTTP PPARG
2 growth/size/body region MP:0005378 10.06 ADIPOQ HSD11B1 INS LEP MTTP PPARG
3 adipose tissue MP:0005375 10.05 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
4 homeostasis/metabolism MP:0005376 10.01 ADIPOQ HSD11B1 INS LEP MTTP PPARG
5 hematopoietic system MP:0005397 9.98 ADIPOQ HSD11B1 INS LEP MTTP PPARG
6 endocrine/exocrine gland MP:0005379 9.95 ADIPOQ HSD11B1 INS LEP PPARG SLC2A4
7 immune system MP:0005387 9.91 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
8 liver/biliary system MP:0005370 9.86 ADIPOQ HSD11B1 INS LEP MTTP PPARG
9 integument MP:0010771 9.8 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
10 muscle MP:0005369 9.63 ADIPOQ HSD11B1 INS LEP PPARG SLC2A4
11 nervous system MP:0003631 9.5 ADIPOQ HSD11B1 INS LEP MTTP PPARG
12 renal/urinary system MP:0005367 9.02 ADIPOQ INS LEP PPARG SERPINE1

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

PubMedHealth treatment related to Abdominal Obesity-Metabolic Syndrome 1: 64

Healthy lifestyle changes are the first line of treatment for metabolic syndrome. Lifestyle changes include losing weight, being physically active, following a heart healthy diet, and quitting smoking.If lifestyle changes aren't enough, your doctor may prescribe medicines. Medicines are used to treat and control risk factors such as high blood pressure, high triglycerides, low HDL cholesterol, and high blood sugar.Blood-thinning medicines, such as aspirin, also may be used to reduce the risk of blood clots. Excessive blood clotting is a condition that often occurs with metabolic syndrome.

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 789)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4,Phase 3,Not Applicable 163222-33-1 150311
2
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
3
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
4
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
5
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
6
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1 137862-53-4 60846
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
9
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
10
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
11
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
12
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
13
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
14
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0, 481-30-1 10204 6013
15
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 129722-12-9 60795
16
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
17
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 58-93-5 3639
18
Spironolactone Approved Phase 4,Phase 1,Not Applicable 1952-01-7, 52-01-7 5833
19
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88150-42-9 2162
20
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 158781 130881
21
Losartan Approved Phase 4,Phase 3,Phase 2,Not Applicable 114798-26-4 3961
22
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-66-6 32051
23
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 111025-46-8 4829
24
Ethinyl Estradiol Approved Phase 4,Phase 2,Not Applicable 57-63-6 5991
25
Cyproterone Acetate Approved, Investigational Phase 4,Not Applicable 427-51-0
26
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
27
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134523-00-5 60823
28
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
29
Curcumin Approved, Experimental, Investigational Phase 4,Phase 2,Not Applicable 458-37-7 969516
30
Clozapine Approved Phase 4,Phase 2,Not Applicable 5786-21-0 2818
31
Haloperidol Approved Phase 4,Not Applicable 52-86-8 3559
32
Titanium dioxide Approved Phase 4,Phase 3,Phase 2 13463-67-7
33
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
34
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
35
Irbesartan Approved, Investigational Phase 4,Not Applicable 138402-11-6 3749
36
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
37
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 132539-06-1 4585
38
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
39
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 122320-73-4 77999
40
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Not Applicable 49562-28-9 3339
41
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
42
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
43
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 302-25-0
44
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Not Applicable 2921-57-5
45
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-24-8 5755
46
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 83-43-2 6741
47
Iron Approved, Experimental Phase 4,Not Applicable 7439-89-6, 15438-31-0 27284 23925
48
Allopurinol Approved Phase 4,Phase 2,Not Applicable 315-30-0 2094
49
Ethanol Approved Phase 4,Phase 3,Phase 1,Not Applicable 64-17-5 702
50
Magnesium oxide Approved Phase 4,Phase 2,Phase 3 1309-48-4 14792

Interventional clinical trials:

(show top 50) (show all 2035)
# Name Status NCT ID Phase Drugs
1 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
2 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
3 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
4 Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
5 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
6 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
7 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
8 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
9 Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) Unknown status NCT00790946 Phase 4 Valsartan
10 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
11 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4 metyrapone;placebo
12 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
13 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
14 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
15 Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome Unknown status NCT01271374 Phase 4 amlodipine and olmesartan;losartan and HCTZ
16 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
17 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
18 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
19 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
20 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4 Cholecalciferol;placebo
21 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
22 Korean AMADEUS Study Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
23 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
24 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
25 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
26 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
27 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
28 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
29 Mesoglycan, Vascular Reactivity and Metabolic Syndrome Completed NCT02254850 Phase 4 Mesoglycan;Mesoglycan;Placebo;Placebo
30 PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
31 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 4 Dapagliflozin;Placebo
32 ROMEO (Rosuvastatin in Metabolic syndrOme) Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
33 Oral Contraceptives in the Metabolic Syndrome Completed NCT00205504 Phase 4 Ortho Tri Cyclen
34 Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome Completed NCT00640276 Phase 4 pitavastatin
35 The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome Completed NCT00664742 Phase 4 Fluvastatin XL®
36 Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome Completed NCT00138528 Phase 4 Fluvastatin
37 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome Completed NCT00815659 Phase 4 rosuvastatin
38 Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome Recruiting NCT02295202 Phase 4
39 Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed NCT00110422 Phase 4 Irbesartan;Hydrochlorothiazide
40 Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome Recruiting NCT03440736 Phase 4 Secukinumab
41 The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome Completed NCT00926341 Phase 4 Pioglitazone;Telmisartan
42 Caduet and TLC Intervention in Metabolic Syndrome Completed NCT03504735 Phase 4 Caduet Pill;Placebo
43 Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome Active, not recruiting NCT02252406 Phase 4 Ranolazine;Placebo
44 Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome Recruiting NCT03355469 Phase 4 Low Intensity Exercise + Metformin;High Intensity Exercise + Metformin;Low Intensity Exercise + Placebo;High Intensity Exercise + Placebo
45 Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome Completed NCT00335699 Phase 4 Rosuvastatin
46 Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome Completed NCT01181830 Phase 4 magnesium pidolate;placebo
47 Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome Recruiting NCT02940366 Phase 4 Pitavastatin 4 mg orally daily;Atorvastatin 20 mg orally daily
48 A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial - Recruiting NCT02651454 Phase 4 Daesiho-tang;Jowiseungcheung-tang;Placebo
49 The Effects of Cilnidipine on Metabolic Syndrome Improvement Completed NCT00325936 Phase 4 Cilnidipine
50 Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome Completed NCT01714011 Phase 4 Ziprasidone;Aripiprazole

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

# Genetic test Affiliating Genes
1 Metabolic Syndrome X 30 MTTP

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

42
Liver, Heart, Endothelial, Ovary, Prostate, Bone, Kidney

Publications for Abdominal Obesity-Metabolic Syndrome 1

Articles related to Abdominal Obesity-Metabolic Syndrome 1:

(show top 50) (show all 62)
# Title Authors Year
1
Circulating adipokines and insulin resistance in subjects with combined cardiac and metabolic syndrome X. ( 26413164 )
2015
2
The question of metabolic syndrome X. ( 26631307 )
2015
3
Glycyrrhizin ameliorates insulin resistance, hyperglycemia, dyslipidemia and oxidative stress in fructose-induced metabolic syndrome-X in rat model. ( 23923606 )
2013
4
Central retinal artery occlusion in a patient with metabolic syndrome x. ( 22737328 )
2010
5
Anaesthetic considerations in metabolic syndrome X. ( 20532086 )
2010
6
Beneficial effects of modified egg* on oxidative stress in F1- generation of metabolic syndrome-X induced Wistar rat. ( 19374165 )
2009
7
Cardiac syndrome X versus metabolic syndrome X. ( 17010457 )
2007
8
Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period? ( 17475465 )
2007
9
[The metabolic syndrome X or insulin resistance syndrome]. ( 17304724 )
2007
10
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. ( 16416266 )
2006
11
Aberrant expression of perilipins and 11-beta-HSD-1 as molecular signatures of metabolic syndrome X in south east Asians. ( 16941796 )
2006
12
Long term excessive Zn-supplementation promotes metabolic syndrome-X in Wistar rats fed sucrose and fat rich semisynthetic diet. ( 16999025 )
2006
13
A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. ( 15734832 )
2005
14
Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 15833894 )
2005
15
Pathophysiology of metabolic syndrome X and its links to the perinatal period. ( 15925303 )
2005
16
Low-flow vascular remodeling in the metabolic syndrome X. ( 14644764 )
2004
17
Metabolic syndrome X: an inflammatory condition? ( 14972097 )
2004
18
The metabolic syndrome, formerly called metabolic "syndrome X". ( 15219533 )
2004
19
Swiss Medical Weekly Young Investigator's Award 2003: Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 15243846 )
2004
20
HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure. ( 15470277 )
2004
21
Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. ( 12537988 )
2003
22
Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. ( 12697574 )
2003
23
The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 12756274 )
2003
24
Pathobiology of metabolic syndrome X in obese and non-obese South Asian Indians: further discussion and some suggestions. ( 12781862 )
2003
25
The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. ( 12946657 )
2003
26
Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 12947532 )
2003
27
Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. ( 14574352 )
2003
28
Metabolic syndrome X is common in Indians: but, why and how? ( 14719590 )
2003
29
The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. ( 15028595 )
2003
30
Molecular mechanism of vascular disease in metabolic syndrome X. ( 11872360 )
2002
31
Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. ( 11856814 )
2002
32
Obesity, metabolic syndrome X, and inflammation. ( 11985951 )
2002
33
Metabolic syndrome X--high risk factor for acute myocardial infarction and its complications. ( 12137304 )
2002
34
Metabolic syndrome X is common in South Asians, but why and how? ( 12297221 )
2002
35
The metabolic syndrome X and peripheral cortisol synthesis. ( 12397528 )
2002
36
Is metabolic syndrome X an inflammatory condition? ( 12486208 )
2002
37
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X. ( 12512799 )
2002
38
Unravelling metabolic syndrome X. ( 11427370 )
2001
39
Steroid metabolism in metabolic syndrome X. ( 11469814 )
2001
40
Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. ( 11958275 )
2001
41
Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity. ( 15573024 )
2001
42
Insulin resistance: the metabolic syndrome X ( 10713753 )
2000
43
Metabolic syndrome X: a review. ( 10863169 )
2000
44
Metabolic syndrome X and fibrinolytic disturbances. ( 10870268 )
2000
45
Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. ( 11057441 )
2000
46
Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogenous Chinese population with normal glucose tolerance. ( 10189006 )
1999
47
Liver pathology and the metabolic syndrome X in severe obesity. ( 10323371 )
1999
48
Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: a potential link between cardiac and metabolic syndrome X. ( 10483984 )
1999
49
The metabolic syndrome X. ( 10842649 )
1999
50
Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. ( 10842660 )
1999

Variations for Abdominal Obesity-Metabolic Syndrome 1

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome

Expression for Abdominal Obesity-Metabolic Syndrome 1

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.

Pathways for Abdominal Obesity-Metabolic Syndrome 1

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 ADIPOQ INS LEP PPARG SLC2A4
2
Show member pathways
12.6 ADIPOQ LEP PPARG SLC2A4
3
Show member pathways
12.45 ADIPOQ INS LEP SLC2A4
4 12.2 ADIPOQ INS PPARG SLC2A4
5
Show member pathways
12.07 ADIPOQ INS LEP PPARG SLC2A4
6
Show member pathways
11.92 INS LEP SLC2A4
8
Show member pathways
11.85 ADIPOQ INS PPARG
9
Show member pathways
11.59 ADIPOQ INS SLC2A4
10 11.38 ADIPOQ LEP SLC2A4
11 11.28 LEP SLC2A4
12 11.26 INS LEP
13 11.22 ADIPOQ INS LEP PPARG SERPINE1 SLC2A4
14 11.19 INS SLC2A4
15 11 INS SLC2A4
16 10.9 ADIPOQ LEP PPARG
17 10.66 INS SLC2A4
18 10.6 ADIPOQ LEP PPARG SLC2A4

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.85 HSD11B1 LEP MTTP PPARG
2 regulation of signaling receptor activity GO:0010469 9.8 ADIPOQ INS LEP SERPINE1
3 fatty acid beta-oxidation GO:0006635 9.61 ADIPOQ LEP
4 response to activity GO:0014823 9.61 ADIPOQ LEP
5 placenta development GO:0001890 9.6 LEP PPARG
6 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.59 ADIPOQ PPARG
7 positive regulation of glucose import GO:0046326 9.58 ADIPOQ INS
8 brown fat cell differentiation GO:0050873 9.58 ADIPOQ SLC2A4
9 response to ethanol GO:0045471 9.58 ADIPOQ LEP SLC2A4
10 positive regulation of interleukin-8 production GO:0032757 9.57 ADIPOQ SERPINE1
11 lipoprotein transport GO:0042953 9.56 MTTP PPARG
12 positive regulation of cellular protein metabolic process GO:0032270 9.54 ADIPOQ INS
13 cellular response to insulin stimulus GO:0032869 9.54 ADIPOQ PPARG SLC2A4
14 positive regulation of insulin receptor signaling pathway GO:0046628 9.52 INS LEP
15 regulation of fat cell differentiation GO:0045598 9.51 LEP PPARG
16 response to nutrient GO:0007584 9.5 ADIPOQ LEP PPARG
17 fatty acid oxidation GO:0019395 9.48 ADIPOQ PPARG
18 negative regulation of gluconeogenesis GO:0045721 9.46 ADIPOQ INS
19 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.43 ADIPOQ PPARG
20 glucose metabolic process GO:0006006 9.33 ADIPOQ INS LEP
21 negative regulation of acute inflammatory response GO:0002674 9.26 INS PPARG
22 circadian rhythm GO:0007623 9.26 ADIPOQ LEP MTTP SERPINE1
23 glucose homeostasis GO:0042593 9.02 ADIPOQ INS LEP PPARG SLC2A4

Molecular functions related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 ADIPOQ INS LEP

Sources for Abdominal Obesity-Metabolic Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....